BlueRock Therapeutics — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications1liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
bemdaneprocelStudy BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).	Parkinson	Phase 3	À vérifier	United States, Australia, Canada	À vérifier
bemdaneprocelStudy BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).	Parkinson	Phase 3	À vérifier	United States, Australia, Canada	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
bemdaneprocel	Parkinson	Phase 3	NCT06944522	exPDite-2 — A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease	RECRUITING

Publications

1

Molécule	Indication / population	Titre	Journal	Date
bemdaneprocel		Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease.	Nature